• COVID-19
  • Biosimilars
  • Cataract Therapeutics
  • DME
  • Gene Therapy
  • Workplace
  • Ptosis
  • Optic Relief
  • Imaging
  • Geographic Atrophy
  • AMD
  • Presbyopia
  • Ocular Surface Disease
  • Practice Management
  • Pediatrics
  • Surgery
  • Therapeutics
  • Optometry
  • Retina
  • Cataract
  • Pharmacy
  • IOL
  • Dry Eye
  • Understanding Antibiotic Resistance
  • Refractive
  • Cornea
  • Glaucoma
  • OCT
  • Ocular Allergy
  • Clinical Diagnosis
  • Technology

Generic azelastine ophthalmic solution available

Article

The FDA has granted approval for an abbreviated new drug application to market a generic version of azelastine ophthalmic solution 0.05% (Optivar, Meda Pharmaceuticals), according to Sun Pharmaceutical Industries.

Mumbai, India-The FDA has granted approval for an abbreviated new drug application (ANDA) to market a generic version of azelastine ophthalmic solution 0.05% (Optivar, Meda Pharmaceuticals), according to Sun Pharmaceutical Industries.

Azelastine is a selective antihistamine for the treatment of itching of the eyes associated with allergic conjunctivitis.

Established in 1983, Sun Pharmaceutical Industries manufactures and markets several pharmaceutical formulations as branded generics as well as generics in India, the United States, and several other markets across the world.

Related Videos
Video 2 - 1 KOL is featured in, "Advances in Technology for SMILE procedure"
Video 1 - 1 KOL is featured in, "Overview of Small Incision Lenticule Extraction (SMILE)"
Vicki Chan, MD, shares pearls for leveraging the power of social media in health care
EyeCon 2024: Peter J. McDonnell, MD, marvels on mentoring, modern technology, and ophthalmology’s future
Lorraine Provencher, MD, presenting slides
© 2024 MJH Life Sciences

All rights reserved.